1. Central Cancer Registry Center and Ministry of Health and Welfare. Annual report of the central registry in Korea. 1999.
2. Yang SH, Kim TY, Kim BK, Ko YW, Kwak DK, Kim NK, Kim SH, Kim SR. A statistical study of multiple myeloma in Korea. Korean J Hematol 1995;30:345–361.
3. Barlogie B. In: Kipps T, ed. Plasma cell myeloma. William's hematology. 1995;5th ed. Baltimore: McGrawl-Hill, 1109.
4. Boccadoro M, Marmont F, Tribalto M, Avvisati G, Andriani A, Barbui T, Cantonetti M, Carotenuto M, Comotti B, Dammacco F. Multiple myeloma: VMCP/BAP alternating combination chemotherapy is not superior to melphalan prednisolone even in high-risk patients. J Clin Oncol 1991;9:444–448PMID : 1999714.
5. McElwain TJ, Powles RL. High-dose intravenous melphalan for plasma cell leukemia and myeloma. Lancet 1983;2:822–824PMID : 6137651.
6. Barlogie B, Alexanian R, Dicke KA, Zagars G, Spitzer G, Jagannath S, Horwitz L. High-dose chemoradiotherapy and autologous bone marrow transplantation for resistant multiple myeloma. Blood 1987;70:869–872PMID : 3304465.
7. Attal M, Harousseau JL, Stoppa AM, Sotto JJ, Fuzibet JG, Rossi JF, Casassus P, Maisonneuve H, Facon T, Ifrah H, Payen C, Bataille R. A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. N Engl J Med 1996;335:91–97PMID : 8649495.
8. Barlogie B, Jagannath S, Vesole DH, Naucke S, Cheson B, Mattox S, Bracy D, Salmon S, Jacobson J, Crowley J, Tricort G. Superiority of tandem autologous transplantation over standard therapy of previously untreated multiple myeloma. Blood 1997;89:789–793PMID : 9028309.
9. Attal M, Harousseau JL, Facon T, Guilhot F, Doyen C, Fuzibet JG, Monconduit M, Hulin C, Caillot D, Bouabdallah R, Voillat L, Sotto JJ, Grosbois B, Bataille R. Single versus double autologous stem-cell transplantation for multiple myeloma. N Engl J Med 2003;349:2495–2502PMID : 14695409.
10. Lee JH, Bang S, Lee S, Kim HS, Ahn JS, Cho EK, Lee JA, Ahn MJ, Jo DY, Kim TY, Park YS, Yoon SS, Lee HB, Suh C, Seong CM, Lee SN, Yoon HJ, Kim S, Kim CS, Park S, Cho KS, Kim BK, Kim HC, Park CH, Kim SH. High dose chemotherapy with autologous stem cell transplantation in multiple myeloma. Korean J Hematol 1999;34:306–316.
11. Jacobson JL, Hussein MA, Barlogie B, Durie BG, Crowley JJ. A new staging system for multiple myeloma patients based on the Swothwest Oncology Group (SWOG) experience. Br J Haematol 2003;122:441–450PMID : 12877671.
12. Samson D, Gaminara E, Newland A, van de Pette J, Kearney J, McCarthy D, Joyner M, Aston L, Mitchell T, Hamon M, Barett AJ, Evans M. Infusion of vincristine and doxorubicin with oral dexamethasone as first-line therapy for multiple myeloma. Lancet 1989;2:882–885PMID : 2571813.
13. Barlogie B, Jagannath S, Desikan KR, Mattox S, Vesole D, Siegel D, Tricot G, Munshi N, Fassas A, Singhal S, Mehta J, Anaissie E, Dhodapkar D, Naucke S, Cromer J, Sawyer J, Epstein J, Spoon D, Ayers D, Cheson B, Crowley J. Total therapy with tandem transplants for newly diagnosed multiple myeloma. Blood 1999;93:55–65PMID : 9864146.
14. Harousseau JL, Attal M, Divine M, Marit G, Leblon V, Stoppa AM, Bourhis JH, Caillot D, Boasson M, Abgrall JF. Autologous stem cell transplantation after first remission induction treatment in multiple myeloma: a report of the French Registry on autologous transplantation in multiple myeloma. Blood 1995;85:3077–3085PMID : 7756641.
15. Cunningham D, Paz-Ares L, Milan S, Powles R, Nicolson M, Hickish T, Selby P, Treleavan J, Viner C, Malpas J. High dose melphalan and autologous bone marrow transplantation as consolidation in previously untreated myeloma. J Clin Oncol 1994;12:759–763PMID : 8151319.
16. Fermand JP, Chevret S, Ravaud P, Divine M, Leblond V, Dreyfus F, Meriette X, Broute JC. High dose chemotherapy and autologous blood stem cell transplantation in multiple myeloma: results of a phase II trial involving 63 patients. Blood 1993;82:2005–2009PMID : 8104534.
17. Blade J, San Miguel JF, Fontanillas M, Alcala A, Maldonado J, Gracia Conde J, Conde E, Conzalez-Brito G, Moro MJ, Escudero ML, Trujillo J, Pascual A, Rozman C, Estape J, Montserrat E. Survival of multiple myeloma patients who are potential candidates for early high dose therapy intensification / autotransplantation and who were conventionally treated. J Clin Oncol 1996;14:2167–2173PMID : 8683251.
18. Corradini P, Voena C, Astolfi M, Ladetto M, Tarella C, Bocadoro M, Pileri A. High-dose sequential chemotherapy in multiple myeloma: residual tumor cells are detectable in bone marrow and peripheral blood cell harvests and after autografting. Blood 1995;85:1596–1602PMID : 7888677.
19. Davies FE, Rawstorn AC, Owen RG, Morgan GJ. Minimal residual disease monitoring in multiple myeloma. Best Pract Res Clin Haematol 2002;15:197–222PMID : 11987924.
20. Harousseau JL. In: Broudy VC, Abkowitz JL, Vose JM, Bajus JL, eds. Role of transplantation in myeloma. Hematology. 2002;Washington: American Society of Hematology, 221–227.
21. Alexnian R, Weber D, Giralt S, Delasalle K. Consolidation therapy of multiple myeloma with thalidomide-dexamethasone after intensive chemotherapy. Ann Oncol 2002;13:1116–1119PMID : 12176792.
22. Massaia M. Idiotype vaccination of myeloma patients after chemotherapy. Acta Oncol 2000;39:807–808PMID : 11145437.
23. Liso A, Stokerl-Goldenstein KE, Auffermann-Gretzinger S, Benike CJ, Reichardt V, van Beckhoven A, Rajapaksa R, Enlgemen EG, Bleme KG, Levy R. Idiotype vaccination using dendritic cells after autologous peripheral blood progenitor cell transplantation for multiple myeloma. Biol Blood Marrow Transplant 2000;6:621–627PMID : 11128812.
24. Kroger N, Schwerdtfeger R, Kiehl M, Sayer HG, Renges H, Zabelina T, Fehse B, Tgel F, Wittkowsky G, Kuse R, Zander AR. Autologous stem cell transplantation followed by a dose-reduced allograft induces high complete remission rate in multiple myeloma. Blood 2002;100:755–760PMID : 12130482.
25. Facon T, Avet-Loiseau H, Guillerm G, Moreau P, Genevieve F, Zandecki M, Lai JL, Leleu X, Jouet JP, Bauters F, Harousseau JL, Bataille R, Mary JY. Chromosome 13 abnormalities identified by FISH analysis and serum β
2-microglobulin produce powerful myeloma staging system for patients receving high-dose therapy. Blood 2001;97:1566–1571PMID : 11238092.